Arrowhead net loss widens to $194.28 million in FY26 Q3; revenue rises to $75.25 million
PUBT · 1d ago
Share
Listen to the news
- Arrowhead posted fiscal 2026 Q3 revenue of USD 75.25 million, up 170.99% year over year.
- Net loss attributable to shareholders widened to USD 194.28 million; diluted loss per share deepened to USD 1.36.
- R&D expense climbed to USD 198.22 million; SG&A rose to USD 47.12 million.
- Total cash resources increased to USD 1.57 billion as of June 30, 2026.
- REDEMPLO prescriptions roughly doubled; plozasiran Phase 3 SHASTA-3/4 met endpoints with 79%-81% median triglyceride reductions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260804998802) on August 04, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending